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The management of patients with renal impairment is a challenge. Such patients frequently have multiple system involvement and require appropriate therapy, but renal impairment affects drug metabolism and makes drug interactions likely
The author, Dr. Günter Seyffart, has had a lifelong interest in this subject and has contributed in very important ways to our current understanding of how drugs can be more safely used in patients with kidney disease. In this directory about 1500 drugs are covered with very specific recommendations (contraindications dosage modifications, and potential nephrotoxicity) concerning use in patients with kidney disease. Such a comprehensive guide, written by an experienced clinical nephrologist, is an invaluable tool for the physician seeking to minimize the risks and optimize the benefits of therapeutic agents in patients with kidney disease of varying severity (as approximated by estimates of the prevailing level of GFR). The systematic approach taken provides not only clarity of exposition but also greatly enhances the practical utility of the Directory. This Directory will help to avoid catastrophes and modulate the risk of adverse events due to drug use in patients with kidney disease. Prevention is an often used byword in medicine -this monograph brings prevention to the bedside. 
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